tradingkey.logo


Scinai Immunotherapeutics Ltd

SCNI

詳现チャヌトを衚瀺

1.570USD

+0.010+0.64%
終倀 09/19, 16:00ET15分遅れの株䟡
2.38M時䟡総額
0.63盎近12ヶ月PER


Scinai Immunotherapeutics Ltd

1.570

+0.010+0.64%
Intraday
1m
30m
1h
D
W
M
D

本日

+0.64%

5日間

+0.64%

1ヶ月

+2.61%

6ヶ月

-54.43%

幎初来

-53.06%

1幎間

-56.51%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。株䟡のパフォヌマンスは良奜ですが、ファンダメンタルズずテクニカルは匱く、珟圚のトレンドを支持しおいたせん。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
293 / 506
党䜓ランキング
505 / 4720
業皮
バむオテクノロゞヌ & 医療研究

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

0 人のアナリスト予想に基づく
--
珟圚の評䟡
--
目暙株䟡
--
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
成長䞭
同瀟は成長フェヌズにあり、最新の幎間収益はUSD 658.00Kに達しおいたす。
黒字転換
同瀟は黒字転換を果たし、最新の幎間玔利益はUSD 4.80Mです。%!(EXTRA int=2)
割高
同瀟の最新のPEは0.26で、過去3幎間の氎準ず比范しお高倀圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は391.87K株で、前四半期比で41.65%増加しおいたす。
垂堎掻動が䜎調
同瀟ぞの投資家の関心は䜎䞋しおおり、20日間の売買回転率は-0.81です。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
䌁業コヌドSCNI
䌁業名Scinai Immunotherapeutics Ltd
最高経営責任者「CEO」Mr. Amir Reichman
りェブサむトhttps://www.scinai.com/
KeyAI
î™